Trials / Completed
CompletedNCT02115204
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
Adjuvant Chemotherapy of Breast Cancer: Sequential Chemotherapy vs. Standard Therapy. Prospective Randomised Comparison of 4 x Epirubicin and Cyclophosphamide (EC) --> 4 x Docetaxel (Doc) vs. 6 x CMF / CEF in Patients With 1 to 3 Positive Lymph Nodes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,011 (actual)
- Sponsor
- West German Study Group · Academic / Other
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. West German Study Group and "Arbeitsgemeinschaft Gynäkologische Onkologie" (WSG-AGO) EC-Doc is a large trial evaluating modern sequential taxane-based chemotherapy in the subgroup with 1-3 involved lymph nodes (LN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epirubicin | |
| DRUG | Cyclophosphamide | |
| DRUG | Docetaxel | |
| DRUG | Methotrexate | |
| DRUG | 5-fluorouracil |
Timeline
- Start date
- 2000-06-01
- Primary completion
- 2005-08-01
- Completion
- 2010-08-01
- First posted
- 2014-04-15
- Last updated
- 2019-10-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02115204. Inclusion in this directory is not an endorsement.